After adjustment for age, sex, baseline BMI, baseline HbA1c, and hepatosteatosis grade, semaglutide remained independently associated with greater percentage weight loss at 6 months (adjusted = 6.16% points
Treatment effects estimated by LOCF-based analyses Historically, participants in weight management trials who discontinued their allocated treatment were often censored from the trial, resulting in no or few post-discontinuation weight assessments available for the statistical analysis [24]
Dosing of Brand vs
In OASIS 4, those on the 25 mg dose lost nearly 14% of their body weight after 64 weeks (about 15 months)
Identifying the Ideal Candidate Prospective participants for semaglutide weight loss should have a BMI of 30 or more, or 27 coupled with related conditions like hypertension or type 2 diabetes
This may include orlistat (Xenical/Alli) or, in certain regions, phentermine for short-term use